Bristol Myers Squibb BMY spent $2.2M on lobbying in Q3 2023 · Health Issues, Medicare and 2 more issues

Trade details

Type: Lobbying report
Amount: $2,180,000
Quarter: Q3 2023
Stock: Bristol Myers Squibb BMY
Client: Bristol-Myers Squibb Company
Reported: 23/10/20

Down 2.2% from last quarter

What else happened in Bristol Myers Squibb around then

Filed or reported within 30 days of the trade day · 23/08/31~23/10/30

Bristol-Myers Squibb Company's other lobbying reports

Bristol-Myers Squibb Company
LobbyingBristol Myers Squibb
Lobbying
Bristol Myers Squibb
BMY
$50K
$50K
Reported 07/20
for Q2
Bristol-Myers Squibb Company
LobbyingBristol Myers Squibb
Lobbying
Bristol Myers Squibb
BMY
$80K
$80K
Reported 07/20
for Q2
Bristol-Myers Squibb Company
LobbyingBristol Myers Squibb
Lobbying
Bristol Myers Squibb
BMY
$3.2M
$3.2M
Reported 07/20
for Q2
Bristol-Myers Squibb Company
LobbyingBristol Myers Squibb
Lobbying
Bristol Myers Squibb
BMY
Under $5,000
Under $5,000
Reported 07/20
for Q2
Bristol-Myers Squibb Company
LobbyingBristol Myers Squibb
Lobbying
Bristol Myers Squibb
BMY
$60K
$60K
Reported 07/20
for Q2

Bristol Myers Squibb BMY spent $2.2M on lobbying in Q3 2023 · Health Issues, Medicare and 2 more issues | Whalegun